Unique Gut Bacteria with Deep Therapeutic Benefit Potential
Christensenella is a particularly promising keystone gut bacteria and YSOPIA is the first biotech company to harness its tremendous therapeutic potential.
Since its discovery in 2012, an increasing body of evidence have shown that Christensenellaceae family plays a major role in the development of a healthy gut microbiome and is missing in many chronic diseases patients.
“The Christensenellaceae, a recently described family in the phylum Firmicutes, is emerging as an important player in human health.
The relative abundance of Christensenellaceae in the human gut is inversely related to host body mass index (BMI) in different populations and multiple studies, making its relationship with BMI the most robust and reproducible link between the microbial ecology of the human gut and metabolic disease reported to date.
The family is also related to a healthy status in a number of other different disease contexts, including obesity and inflammatory bowel disease. In addition, Christensenellaceae is highly heritable across multiple populations, although specific human genes underlying its heritability have so far been elusive.
Further research into the microbial ecology and metabolism of these bacteria should reveal mechanistic underpinnings of their host-health associations and enable their development as therapeutics.”
Waters et al., The human gut bacteria Christensenellaceae are widespread, heritable, and associated with health, 2019, BMC Biology
Missing Keystone in Many Chronic Diseases
Christensenella bears high potential to be a source of innovative treatments for multiple chronic diseases.
In 2014, it was identified as the most heritable bacterial taxon in humans and was found to be significantly reduced in obese European individuals (Goodrich et al. 2014).
These observations were rapidly confirmed in an independent study in 2015 (Fu et al. 2015). In addition, high levels of C. minuta in the 2015 cohort were associated with reduced circulating levels of triglycerides and higher HDL cholesterol (also known as “good” cholesterol).
This association was recently validated in a large Dutch cohort of more than 2000 people where Christensenellaceae were consistently associated with low VLDL (“bad cholesterol”), high HDL (“good cholesterol”) and low serum triglycerides (Vojinovic et al. 2019).
LNC Therapeutics becomes
YSOPIA bioscience
« This new name, YSOPIA Bioscience, symbolizes the major success of our teams in advancing to the clinic, in line with our ambition to become a major player in developing ground-breaking therapies based on the gut microbiome potential »
Dr Georges RAWADI, CEO
~ more ABOUT IT